{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:34:30Z","timestamp":1783402470835,"version":"3.54.6"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Region \u00d6rebro County research commitee","award":["OLL-929736"],"award-info":[{"award-number":["OLL-929736"]}]},{"name":"Region \u00d6rebro County research commitee","award":["OLL-783961"],"award-info":[{"award-number":["OLL-783961"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Currently, cervical cancer prevention is undergoing comprehensive development regarding human papillomavirus (HPV) vaccination and cervical cancer screening. In Sweden and many other countries, high coverage vaccinated cohorts are entering screening within the next few years. This entails demands for baseline HPV genotype data across the screening age range for surveillance and a basis for screening program adjustment. In 2016, \u00d6rebro County, Sweden, changed to primary HPV screening using HPV mRNA testing followed by cytology triage. An alternative triage method to cytology could allow for a fully molecular screening algorithm and be implemented in a screening program where self-sampling is included. Hypermethylation analysis of the human genes FAM19A4\/miR124-2 has been suggested as a promising triage method. HPV mRNA-positive screening samples (n = 529) were included and subjected to genotyping targeting a broad range of both low-risk and high-risk genotypes in addition to hypermethylation analysis of the two human genes FAM19A4\/miR124-2. Data were connected to cytological and histological status and age. The most commonly detected genotypes were HPV31, 16, and 52. In addition, HPV18 was one of the most common genotypes in high-grade squamous intraepithelial lesions (HSILs) samples. In relation to available vaccines, 26% of the women with histological HSIL or cancer (\u2265HSIL) tested positive for only hrHPV included in the quadrivalent vaccine and 77% of the genotypes in the nonavalent vaccine. According to these figures, a relatively large proportion of the HSILs will probably remain, even after age cohorts vaccinated with the quadrivalent vaccine enter the screening program. Hypermethylation positivity was associated with increasing age, but no HPV-related independently predictive factors were found. Accordingly, age needs to be considered in development of future screening algorithms including triage with hypermethylation methodology.<\/jats:p>","DOI":"10.1371\/journal.pone.0274825","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T18:25:07Z","timestamp":1663871107000},"page":"e0274825","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Full genotyping and FAM19A4\/miR124-2 methylation analysis in high-risk human papillomavirus\u2013positive samples from women over 30 years participating in cervical cancer screening in \u00d6rebro, Sweden"],"prefix":"10.1371","volume":"17","author":[{"given":"Malin","family":"Kaliff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Lillsunde Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Helenius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats G.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-1542","authenticated-orcid":true,"given":"Lovisa","family":"Bergengren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"issue":"1","key":"pone.0274825.ref001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"JM Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"pone.0274825.ref002","author":"International Human Papillomavirus Reference Center","year":"2020","journal-title":"Human papillomavirus reference clones Stockholm the Karolinska Institutet"},{"key":"pone.0274825.ref003","author":"International Agency for Research on Cancer","year":"2012"},{"issue":"2","key":"pone.0274825.ref004","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"M Arbyn","year":"2020","journal-title":"Lancet Glob Health"},{"key":"pone.0274825.ref005","article-title":"Screening f\u00f6r livmoderhalscancer\u2013Rekommendation och bedomningsunderlag [cited 2015 juni]","author":"Swedish National Board of Health and Welfare","journal-title":"Artikelnr 2015-6-39"},{"issue":"3","key":"pone.0274825.ref006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ijc.25726","article-title":"Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study","volume":"129","author":"J Monsonego","year":"2011","journal-title":"Int J Cancer"},{"issue":"Suppl 5","key":"pone.0274825.ref007","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"M Arbyn","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"pone.0274825.ref008","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01177-18","article-title":"Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany","volume":"57","author":"T Iftner","year":"2019","journal-title":"J Clin Microbiol"},{"key":"pone.0274825.ref009","article-title":"HPV-mRNA AND HPV-DNA DETECTION IN SAMPLES TAKEN UP TO SEVEN YEARS BEFORE SEVERE DYSPLASIA OF CERVIX UTERI","author":"O Forslund","year":"2018","journal-title":"Int J Cancer"},{"issue":"2","key":"pone.0274825.ref010","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2019.06.002","article-title":"Long-term CIN3+ risk of HPV positive women after triage with FAM19A4\/miR124-2 methylation analysis","volume":"154","author":"S Dick","year":"2019","journal-title":"Gynecol Oncol"},{"key":"pone.0274825.ref011","article-title":"FAM19A4\/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study","author":"FJ Vink","year":"2019","journal-title":"Int J Cancer"},{"issue":"16","key":"pone.0274825.ref012","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"D Solomon","year":"2002","journal-title":"JAMA"},{"key":"pone.0274825.ref013","volume-title":"WHO Classification of Tumors of The Female Reproductive Organs","author":"RJ Kurman","year":"2014"},{"key":"pone.0274825.ref014","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jviromet.2016.05.015","article-title":"HPV Genotyping from the high risk mRNA Aptima assay- a direct approach using DNA from Aptima sample tubes","volume":"235","author":"G Lillsunde Larsson","year":"2016","journal-title":"J Virol Methods"},{"issue":"2","key":"pone.0274825.ref015","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.5301\/jbm.5000191","article-title":"HPV testing of biobanked liquid-based cytology\u2014a validation study","volume":"31","author":"GL Larsson","year":"2016","journal-title":"Int J Biol Markers"},{"key":"pone.0274825.ref016","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12885-016-2518-4","article-title":"Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study","volume":"16","author":"S Preisler","year":"2016","journal-title":"BMC Cancer"},{"key":"pone.0274825.ref017","author":"Hologic","year":"2017","journal-title":"Aptima HPV Assay Massachusetts, USA"},{"issue":"2","key":"pone.0274825.ref018","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/JCM.02147-10","article-title":"Aptima HPV E6\/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer","volume":"49","author":"S Ratnam","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"11","key":"pone.0274825.ref019","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/bjc.2013.647","article-title":"Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland","volume":"109","author":"MK Leinonen","year":"2013","journal-title":"Br J Cancer"},{"key":"pone.0274825.ref020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/1471-2334-14-413","article-title":"HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system","volume":"14","author":"J Bonde","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0274825.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","article-title":"Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Systematic Review","volume":"24","author":"JH Bonde","year":"2020","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"pone.0274825.ref022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ygyno.2015.01.551","article-title":"Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial","volume":"137","author":"J Monsonego","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"pone.0274825.ref023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2018.12.024","article-title":"Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, \u226525years of age, with NILM cytology","volume":"153","author":"MH Stoler","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"10197","key":"pone.0274825.ref024","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"M Drolet","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"pone.0274825.ref025","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41416-018-0053-6","article-title":"Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer","volume":"118","author":"C Lagheden","year":"2018","journal-title":"Br J Cancer"},{"issue":"1","key":"pone.0274825.ref026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","article-title":"Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis","volume":"89","author":"GM Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"7","key":"pone.0274825.ref027","doi-asserted-by":"crossref","first-page":"e029017","DOI":"10.1136\/bmjopen-2019-029017","article-title":"Role of FAM19A4\/miR124-2 methylation analysis in predicting regression or non-regression of CIN2\/3 lesions: a protocol of an observational longitudinal cohort study","volume":"9","author":"WW Kremer","year":"2019","journal-title":"BMJ Open"},{"issue":"12","key":"pone.0274825.ref028","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1158\/1940-6207.CAPR-14-0237","article-title":"Methylation analysis of the FAM19A4 gene in cervical scrapes is highly efficient in detecting cervical carcinomas and advanced CIN2\/3 lesions","volume":"7","author":"LM De Strooper","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"issue":"9","key":"pone.0274825.ref029","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-17-3251","article-title":"Human Papillomavirus DNA Methylation as a Biomarker for Cervical Precancer: Consistency across 12 Genotypes and Potential Impact on Management of HPV-Positive Women","volume":"24","author":"MA Clarke","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"pone.0274825.ref030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1159\/000450595","article-title":"Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention","volume":"60","author":"AT Lorincz","year":"2016","journal-title":"Acta Cytol"},{"issue":"6","key":"pone.0274825.ref031","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3892\/etm.2021.10916","article-title":"Epigenetic approaches for cervical neoplasia screening (Review)","volume":"22","author":"A Albulescu","year":"2021","journal-title":"Exp Ther Med."},{"key":"pone.0274825.ref032","article-title":"How many Human Papillomavirus types do we need to screen for?","author":"K Sundstr\u00f6m","year":"2020","journal-title":"J Infect Dis"},{"issue":"11","key":"pone.0274825.ref033","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1055-9965.EPI-19-0239","article-title":"Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia","volume":"28","author":"R Adcock","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"pone.0274825.ref034","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1159\/000497286","article-title":"Spontaneous Regression of Cervical Intraepithelial Neoplasia 2: A Meta-analysis","volume":"84","author":"J Zhang","year":"2019","journal-title":"Gynecol Obstet Invest."},{"issue":"4","key":"pone.0274825.ref035","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ijc.29824","article-title":"Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16\/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient population (COMETH study).","volume":"138","author":"R Luttmer","year":"2016","journal-title":"Int J Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T18:25:49Z","timestamp":1663871149000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274825"}},"subtitle":[],"editor":[{"given":"Cecilia","family":"Acuti Martellucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274825","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}